Price of Soliris Far Too High, as Efgartigimod’s Likely Will Be: ICER

Price of Soliris Far Too High, as Efgartigimod’s Likely Will Be: ICER

309883

Price of Soliris Far Too High, as Efgartigimod’s Likely Will Be: ICER

The Institute for Clinical and Economic Review (ICER), an independent nonprofit that evaluates the prices and benefits of medications in the U.S., reported on the efficacy and cost-effectiveness of Soliris (eculizumab) and efgartigimod. Its report found reasonable evidence that adding either of these medications to conventional care could ease symptoms of generalized myasthenia gravis (gMG). But the price of Soliris would need to come down by at least 97% for the medication to be cost-effective,…

You must be logged in to read/download the full post.